" class="no-js "lang="en-US"> Bristol Myers Squibb Archives - Medtech Alert
Wednesday, May 31, 2023

Sort by:


Top Post

SNIPR Biome Reports Positive Clinical Interim Results for Groundbreaking, First-in-Human, CRISPR-based Microbial Gene Therapy

SNIPR Biome, the company pioneering CRISPR microbial gene therapy, has announced positive interim clinical results […]

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

Tubulis and Bristol Myers Squibb today announced that they have entered into a strategic license […]

Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic Development

Foundation Medicine, a pioneer in molecular profiling for cancer announced today, an expanded collaboration with […]

CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs

CHARM Therapeutics, a 3D deep learning biotechnology company discovering and developing transformational medicines, today announced […]

Roche Announces Collaboration With Bristol Myers Squibb to Advance Personalised Healthcare Through Digital Pathology Solutions

Roche (SIX: RO, ROG;OTCQX: RHHBY) today announced that it has entered into a collaboration with Bristol […]

Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo® in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in […]

Compugen Announces Collaboration Expansion with Bristol Myers Squibb Alongside $20 Million Equity Investment

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today […]

Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Bristol Myers Squibb (NYSE:BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of […]

Huyabio International Collaboration with Bristol Myers Squibb in Melanoma

HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that it […]

  1. Cumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer’s Dementia Validation Trial Read more
  2. Cartography Biosciences Expands Scientific Advisory Board with Leading Antibody and Bi-specific Experts Read more
  3. Mission Bio Launches Tapestri v3 to Rapidly Accelerate Rare Cell Detection Applications for Translational Research and Precision Therapeutics Read more
  4. Ostentus Therapeutics and City of Hope to Continue Studies of Novel OST Natural Products for Treatment of Leukemia and Other Cancers Read more
  5. Cellular Origins launches Constellation, its Configurable Robotic Platform to Enable Scalable Manufacture of Advanced Therapies Read more